Download PDF
Zentralbl Gynakol 2005; 127(4): 235-241
DOI: 10.1055/s-2005-836562
Übersicht

© Georg Thieme Verlag Stuttgart · New York

Therapie-induzierte Leukämien - ein zu wenig beachtetes Problem der medikamentösen Tumortherapie?

Therapy-induced Leukemia - An Underestimated Complication of Antineoplastic Chemotherapy?U. Dührsen1
  • 1Klinik für Hämatologie, Universitätsklinikum Essen
Further Information

Publication History

Publication Date:
22 July 2005 (online)

    Permissions and Reprints

Zusammenfassung

Alkylanzien und Topoisomerase-II-Hemmstoffe können Therapie-induzierte akute myeloische Leukämien und Myelodysplasien auslösen. Die Häufigkeit des Auftretens hängt von der Art der verwendeten Substanz, ihrer Dosierung und der Behandlungsdauer ab. Mit den in der adjuvanten Therapie des Mammakarzinoms üblicherweise verwendeten Therapieprotokollen, wie dem CMF- oder AC-Schema, liegt die Leukämierate nach 10 Jahren bei 0,2 bis 0,5 %. Eine Intensivierung der Chemotherapie oder zusätzliche strahlentherapeutische Maßnahmen führen zu einer deutlichen Zunahme der Leukämieinzidenz. Die schlechte Prognose Therapie-induzierter Leukämien und Myelodysplasien begründet die Forderung nach einer möglichst präzisen Identifikation von Patienten, die von adjuvanten Therapiemaßnahmen tatsächlich profitieren.

Abstract

Alkylating agents and topoisomerase II inhibitors are mutagenic cytotoxic drugs which may induce therapy-related acute myeloid leukemia or myelodysplasia. The frequency of these complications depends on the type of agent used, its dosage, and the duration of treatment. Commonly used protocols for adjuvant chemotherapy of breast cancer, such as the CMF or AC protocols, are associated with a leukemia rate of 0.2 to 0.5 % after 10 years. Intensification of chemotherapy or additional radiotherapy lead to a significant increase in the incidence of leukemia. The prognosis of therapy-related leukemia is dismal. Therefore, it appears mandatory to restrict adjuvant chemotherapy to those patients who are the most likely to benefit from it.

Schlüsselwörter

Chemotherapie - Leukämie - Mammakarzinom - Myelodysplasie - Strahlentherapie

Key words

chemotherapy - leukemia - breast cancer - myelodysplasia - radiotherapy

Literatur

  • 1 Shapiro C L, Recht A. Side effects of adjuvant treatment of breast cancer.  N Engl J Med. 2001;  344 1997-2008
    CrossrefPubMedSearch in Google Scholar
  • 2 Levine E G, Bloomfield C D. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.  Semin Oncol. 1992;  19 47-84
    PubMedSearch in Google Scholar
  • 3 Karp J E, Smith M A. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention.  Semin Oncol. 1997;  24 103-113
    PubMedSearch in Google Scholar
  • 4 Kollmannsberger C, Hartmann J T, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.  J Cancer Res Clin Oncol. 1998;  124 207-214
    CrossrefPubMedSearch in Google Scholar
  • 5 Weldon C B, Jaffe B M, Kahn M J. Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: an underemphasized clinical problem.  Ann Surg Oncol. 2002;  9 738-744
    CrossrefPubMedSearch in Google Scholar
  • 6 World Health Organization .Classification of Tumours - Pathology and Genetics - Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
  • 7 Curtis R E, Boice J D, Moloney W C, Ries L G, Flannery J T. Leukemia following chemotherapy for breast cancer.  Cancer Res. 1990;  50 2741-2746
    PubMedSearch in Google Scholar
  • 8 Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R. et al . Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.  Ann Intern Med. 1985;  103 620-625
    CrossrefPubMedSearch in Google Scholar
  • 9 Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R. et al . Proposals for the classification of the myelodysplastic syndromes.  Br J Haematol. 1982;  51 189-199
    PubMedSearch in Google Scholar
  • 10 Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G. et al . International scoring system for evaluating prognosis in myelodysplastic syndromes.  Blood. 1997;  89 2079-2088
    PubMedSearch in Google Scholar
  • 11 Pagano L, Pulsoni A, Tosti M E, Avvisati G, Mele L, Mele M. et al . Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia.  Br J Haematol. 2001;  112 109-117
    CrossrefPubMedSearch in Google Scholar
  • 12 Pedersen-Bjergaard J, Philip P, Larsen S O, Andersson M, Daugaard G, Ersboll J. et al . Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.  Leukemia. 1993;  7 1975-1986
    PubMedSearch in Google Scholar
  • 13 Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z. et al . Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5 098 unselected cases reported in the literature 1974-2001.  Leukemia. 2002;  16 2366-2378
    CrossrefPubMedSearch in Google Scholar
  • 14 Pedersen-Bjergaard J, Sigsgaard T C, Nielsen D, Gjedde S B, Philip P, Hansen M. et al . Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer.  J Clin Oncol. 1992;  10 1444-1451
    PubMedSearch in Google Scholar
  • 15 Hoffmann L, Möller P, Pedersen-Bjergaard J, Waage A, Pedersen M, Hirsch F R. Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature.  Ann Oncol. 1995;  6 781-788
    PubMedSearch in Google Scholar
  • 16 Carli P M, Sgro C, Parchin-Geneste N, Isambert N, Mugneret F, Girodon F. et al . Increase therapy-related leukemia secondary to breast cancer.  Leukemia. 2000;  14 1014-1017
    CrossrefPubMedSearch in Google Scholar
  • 17 Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 2003;  21 3066-3071
    CrossrefPubMedSearch in Google Scholar
  • 18 Smith R E, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.  J Clin Oncol. 2003;  21 1195-1204
    CrossrefPubMedSearch in Google Scholar
  • 19 Curtis R E, Hankey B F, Myers M H, Young J L. Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience.  J Natl Cancer Inst. 1984;  72 531-544
    PubMedSearch in Google Scholar
  • 20 Fisher B, Rockette H, Fisher E R, Wickerham D L, Redmond C, Brown A. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience.  J Clin Oncol. 1985;  3 1640-1658
    PubMedSearch in Google Scholar
  • 21 Haas J F, Kittelmann B, Mehnert W H, Staneczek W, Möhner M, Kaldor J M. et al . Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.  Br J Cancer. 1987;  55 213-218
    PubMedSearch in Google Scholar
  • 22 Curtis R E, Boice J D, Stovall M, Bernstein L, Greenberg R S, Flannery J T. et al . Risk of leukemia after chemotherapy and radiation treatment for breast cancer.  N Engl J Med. 1992;  326 1745-1751
    PubMedSearch in Google Scholar
  • 23 Diamandidou E, Buzdar A U, Smith T L, Frye D, Witjaksono M, Hortobagyi G N. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.  J Clin Oncol. 1996;  14 2722-2730
    PubMedSearch in Google Scholar
  • 24 Bernard-Marty C, Mano M, Paesmans M, Accettura C, Munoz-Bermeo R, Richard T. et al . Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.  Ann Oncol. 2003;  14 693-698
    CrossrefPubMedSearch in Google Scholar
  • 25 Valagussa P, Moliterni A, Terenziani M, Zambetti M, Bonadonna G. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer.  Ann Oncol. 1994;  5 803-808
    PubMedSearch in Google Scholar
  • 26 Tallman M S, Gray R, Bennett J M, Variakojis D, Robert N, Wood W C. et al . Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.  J Clin Oncol. 1995;  13 1557-1563
    PubMedSearch in Google Scholar
  • 27 Yagita M, Ieki Y, Onishi R, Huang C L, Adachi M, Horiike S. et al . Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.  Int J Oncol. 1998;  13 91-96
    PubMedSearch in Google Scholar
  • 28 Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury G J, Mehta J. et al . Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.  Br J Cancer. 2000;  83 91-94
    CrossrefPubMedSearch in Google Scholar
  • 29 Chaplain G, Milan C, Sgro C, Carli P M, Bonithon-Kopp C. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study.  J Clin Oncol. 2000;  18 2836-2842
    PubMedSearch in Google Scholar
  • 30 Cremin P, Flattery M, McCann S R, Daly P A. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin.  Ann Oncol. 1996;  7 745-746
    PubMedSearch in Google Scholar
  • 31 Linassier C, Barin C, Calais G, Letortorec S, Bremond J L, Delain M. et al . Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy.  Ann Oncol. 2000;  11 1289-1294
    CrossrefPubMedSearch in Google Scholar
  • 32 Arriagada R, Gutierrez J. Anthracyclines: is more, better and/or more dangerous?.  Ann Oncol. 2003;  14 663-665
    CrossrefPubMedSearch in Google Scholar
  • 33 Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P. et al . Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.  Lancet. 2000;  356 1384-1391
    CrossrefPubMedSearch in Google Scholar
  • 34 Roman-Unfer S, Bitran J D, Hanauer S, Johnson L, Rita D, Booth C. et al . Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer.  Bone Marrow Transplant. 1995;  16 163-168
    PubMedSearch in Google Scholar
  • 35 Laughlin M J, McGaughey D S, Crews J R, Chao N J, Rizzieri D, Ross M. et al . Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.  J Clin Oncol. 1998;  16 1008-1012
    PubMedSearch in Google Scholar
  • 36 Kröger N, Zander A R, Martinelli G, Ferrante P, Moraleda J M, Da Prada G A. et al . Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.  Ann Oncol. 2003;  14 554-558
    CrossrefPubMedSearch in Google Scholar
  • 37 Stone R M, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe S N. et al . Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.  J Clin Oncol. 1994;  12 2535-2542
    PubMedSearch in Google Scholar
  • 38 Miller J S, Arthur D C, Litz C E, Neglia J P, Miller W J, Weisdorf D J. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy.  Blood. 1994;  83 3780-3786
    PubMedSearch in Google Scholar
  • 39 Friedberg J W, Neuberg D, Stone R M, Alyea E, Jallow H, LaCasce A. et al . Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.  J Clin Oncol. 1999;  17 3128-3135
    PubMedSearch in Google Scholar
  • 40 Sobecks R M, Le Beau M M, Anastasi J, Williams S F. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.  Bone Marrow Transplant. 1999;  23 1161-1165
    CrossrefPubMedSearch in Google Scholar
  • 41 Govindarajan R, Jagannath S, Flick J T, Vesole D H, Sawyer J, Barlogie B. et al . Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma.  Br J Haematol. 1996;  95 349-353
    CrossrefPubMedSearch in Google Scholar
  • 42 Seymour J F, Juneja S K, Campbell L J, Ellims P H, Estey E H, Prince H M. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.  Leukemia. 1999;  13 1735-1740
    CrossrefPubMedSearch in Google Scholar
  • 43 Preston D L, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A. et al . Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987.  Radiat Res. 1994;  137 (2 Suppl) S68-S97
    PubMedSearch in Google Scholar
  • 44 Curtis R E, Boice J D, Stovall M, Flannery J T, Moloney W C. Leukemia risk following radiotherapy for breast cancer.  J Clin Oncol. 1989;  7 21-29
    PubMedSearch in Google Scholar
  • 45 Lavey R S, Eby N L, Prosnitz L R. Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer.  Cancer. 1990;  66 874-881
    PubMedSearch in Google Scholar
  • 46 Andersson M, Storm H H, Mouridsen H T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.  J Natl Cancer Inst. 1991;  83 1013-1017
    PubMedSearch in Google Scholar
  • 47 Rutqvist L E, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Stockholm Breast Cancer Study Group . Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies.  J Natl Cancer Inst. 1995;  87 645-651
    PubMedSearch in Google Scholar
  • 48 Kaldor J M, Day N E, Pettersson F, Clarke E A, Pedersen D, Mehnert W. et al . Leukemia following chemotherapy for ovarian cancer.  N Engl J Med. 1990;  322 1-6
    PubMedSearch in Google Scholar
  • 49 Pedersen-Bjergaard J, Ersboll J, Sorensen H M, Keiding N, Larsen S O, Philip P. et al . Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.  Ann Intern Med. 1985;  103 195-200
    PubMedSearch in Google Scholar
  • 50 Rose P G, Rodriguez M, Waggoner S, Greer B E, Horowitz I R, Fowler J M. et al . Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.  J Clin Oncol. 2000;  18 2957-2962
    PubMedSearch in Google Scholar
  • 51 Henderson I C. Breast cancer therapy - the price of success.  N Engl J Med. 1992;  326 1774-1775
    PubMedSearch in Google Scholar
  • 52 van de Vijver M J, He Y D, van't Veer L J, Dai H, Hart A A, Voskuil D W. et al . A gene-expression signature as a predictor of survival in breast cancer.  N Engl J Med. 2002;  347 1999-2009
    CrossrefPubMedSearch in Google Scholar
  • 53 Wang Y, Klijn J G, Zhang Y, Sieuwerts A M, Look M P, Yang F. et al . Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.  Lancet. 2005;  365 671-679
    CrossrefPubMedSearch in Google Scholar
  • 54 Felix C A, Walker A H, Lange B J, Williams T M, Winick N J, Cheung N K. et al . Association of CYP3A4 genotype with treatment-related leukemia.  Proc Natl Acad Sci U S A. 1998;  95 13 176-13 181
    PubMedSearch in Google Scholar
  • 55 Allan J M, Wild C P, Rollinson S, Willett E V, Moorman A V, Dovey G J. et al . Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.  Proc Natl Acad Sci U S A. 2001;  98 11 592-11 597
    PubMedSearch in Google Scholar
  • 56 Haase D, Binder C, Bünger J, Fonatsch C, Streubel B, Schnittger S. et al . Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.  Leuk Res. 2002;  26 249-254
    CrossrefPubMedSearch in Google Scholar

Prof. Dr. U. Dührsen

Direktor der Klinik für Hämatologie · Zentrum für Innere Medizin · Universitätsklinikum Essen · Universität Duisburg-Essen

Hufelandstraße 55

45122 Essen

Phone: 02 01/7 23 24 17

Fax: 02 01/7 23 59 28

Email: ulrich.duehrsen@uni-essen.de